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Site-directed mutagenesis has been used to delete 2 
residues (Gly4’-Lys4’) from a flexible “loop” region 
between residues 40 and 46 of human dihydrofolate 
reductase. Steady-state kinetic studies show that the 
K, values for the deletion mutant enzyme for both 
dihydrofolate and nicotinamide adenine dinucleotide 
phosphate (reduced) (NADPH) as well as the pH rate 
profile are virtually identical to that of the wild type. 
In contrast, the V,,,,, value of the mutant enzyme is 
decreased 2.5-fold. The results suggest that the loop 
region may play a role in the catalytic efficiency but 
not necessarily in the binding of substrates. Agents 
such as KCl, urea, and organomercurials at concentra- 
tions which show activating effects on the wild-type 
human dihydrofolate reductase have little or no effect 
on the deletion mutant. Competitive enzyme-linked 
immunosorbent assay experiments using peptide-spe- 
cific antibodies against cyanogen bromide fragments 
generated from human dihydrofolate reductase show 
that the binding of folate, NADPH, and methotrexate, 
either in binary or in ternary complexes with the wild- 
type enzyme, causes a striking reduction in the binding 
of the antibodies. Compared with wild type, the bind- 
ing of these ligands with the deletion mutant enzyme 
causes much less inhibition (2-16-fold less) in the bind- 
ing of all three antibodies. The altered properties of 
the mutant enzyme can be explained on the basis of a 
need for the flexible loop 40-46 for reversible protein 
unfolding during activation and also for conforma- 
tional changes induced by ligand binding, thus “com- 
municating” the effects of ligand binding. 
Conformational changes are frequently invoked to account 
for the action of enzymes even though there is often little or 
no information regarding the molecular distortions presumed 
to occur at the active site and in other regions of the protein 
molecule. Elucidating the nature of such changes is important. 
In some cases, it is assumed that the binding of a ligand to 
the active site results in the enzyme being converted to a more 
active conformation and/or a conformation with higher affin- 
ity for substrate. Dihydrofolate reductase (5,6,7,8-tetrahydro- 
folate:NADP+ oxidoreductase, EC 1.5.1.3) (DHFR),’ an im- 
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portant enzyme for maintaining the intracellular pools of 
tetrahydrofolate and its derivatives, is a valid model for in- 
vestigating these effects. 
A critical factor in the efficiency of interaction of substrate 
or folate analogs and NADPH with DHFR is the mutual 
enhancement (up to 1000-fold) of their affinity for the enzyme 
via structural changes induced in the active site (l-4). The 
presence of different conformational states of DHFR in its 
free form uersus complexes with NADPH or folate analogs 
has been established by NMR and fluorescence studies (5-9) 
for bacterial DHFR and by x-ray crystallography for bacterial 
and vertebrate DHFRs (10-12). Our previous studies (13, 14) 
showed that human DHFR (hDHFR) upon binding the li- 
gands folate, NADPH, and methotrexate (MTX)-NADPH 
decreased the binding ability of polyclonal anti-hDHFR pep- 
tide antibodies in regions distant to the active site. These 
results suggested the possible role of regions of the protein 
distant from the active site in communicating the effects of 
ligand binding. Since the secondary structural elements, i.e. 
cY-helices and P-sheets, were not disrupted by ligand binding 
as observed by x-ray crystallography our results indicated 
that the vulnerable antigenic epitopes must reside in the 
flexible “loop” regions. 
Thereafter, in the companion paper (15), we have system- 
atically mapped the antigenic epitopes of hDHFR which 
confirmed our earlier prediction (14) that most of the epitopes 
reside in loop regions at the boundaries of secondary struc- 
tural elements (15). These regions are ideal targets for using 
protein bioengineering methods to study conformational 
changes as related to the functions of DHFR. For this purpose, 
we used oligodeoxynucleotide-directed mutagenesis to delete 
the two residues ( Gly4’, LY&~) from a loop located at residues 
40-46 from the hDHFR cDNA. Tohis loop is a high thermally 
mobile region (16) and is 15-25 A away from the active site 
(17). The mutant hDHFR des[Gly45-Lys46] has been charac- 
terized with respect to its steady-state kinetics, activation 
properties, and protein structure alterations upon ligand bind- 
ing using antibody probes. Our results provide information 
about the important role of this flexible loop region in the 
function of hDHFR. 
EXPERIMENTAL PROCEDURES 
Materials-Restriction endonucleases, T4 polynucleotide kinase, 
and T4 DNA ligase were purchased from Bethesda Research Labo- 
ratories, U. S. Biochemicals, and Boehringer Mannheim, respectively. 
The oligonucleotide-directed in vitro mutagenesis system version 2 
and [cr-%]dATP were purchased from Amersham Corp. DNA se- 
quencing was carried out using the sequence kit from U. S. Biochem- 
icals. MTX was a generous gift from Dr. John A. R. Mead (Division 
of Cancer Treatment, National Cancer Institute). Dihydrofolate 
(FAHZ) was prepared from commercial folic acid by dithionite reduc- 
tion (18). 
Construction of the Human DHFR (DNA) Deletion Mutant-A 20- 
base oligodeoxynucleotide probe (CTTCAGTAGAAGGT AAA CAG -- 
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8028 Mutagenesis of Dihydrofolate Reductase 
AATCTG) used for deletion mutagenesis was synthesized using an 
Applied Biosystems model 380A automated DNA synthesizer and 
was purified on 15% polyacrylamide gel as described by Applied 
Biosystems (DNA Synthesizer User Bulletin 13, 1984). The under- 
lined base triplets coding for Gly45 and LY#~, respectively, were 
deleted. The single-stranded DNA template for the mutagenesis 
reaction was prepared by cloning part of wild-type hDHFR cDNA 
from plasmid pDFR, an expression vector for the hDHFR cDNA 
(19), into M13. Deletion mutagenesis was carried out using an oligo- 
nucleotide-directed in vitro mutagenesis system. Phosphorylation of 
the mutagenic oligonucleotide, annealing of the oligonucleotide with 
DNA template, extension of the oligonucleotide with the Klenow 
fragment of Escherichia coli DNA polymerase I with dCTPaS in place 
of dCTP, filtering of the reaction mixture to remove single-stranded 
DNA, nicking the wild-type strand with NciI, removal of the nicked 
strand with exonuclease III, and repolymerization with E. coli DNA 
polymerase I were carried out according to the instructions of the 
manufacturer. The final product was used to transform E. coli TGl. 
Single-stranded DNA was prepared from five plaques, and DNA from 
each plaque was sequenced (single lane) using the dideoxy sequencing 
method (20, 21) to detect the mutation. 
For cloning of the mutant hDHFR cDNA back into the pDFR 
expression vector, the replicative form of M13containing mutant 
cDNA was prepared and digested with EcoRI and PstI to obtain the 
mutant cDNA fragment. pDFR DNA was digested with EcoRI and 
P&I, and the pDFR vector fragment was then ligated with the mutant 
hDHFR cDNA fragment. The ligation mixture was used to transform 
E. coli JM107. 
The plasmid carrying the mutant hDHFR gene was sequenced by 
the double-stranded dideoxy method (20, 22). To facilitate this work, 
three synthetic primers were used dividing the fragment to be se- 
quenced into three parts of about 200 base pairs each in order to 
cover the entire 558-nucleotide coding sequence. 
Expression and Purification of Mutant hDHFR des[Gly45-Lys’6]- 
JM107 cells containing the mutant plasmids were grown in a ll-liter 
culture at 37 “C in the presence of 50 mg of ampicillin/ml to an 
optical density of 0.6-0.7 (at 600 nm) and induced by the addition of 
5 g of isopropyl+D-thiogalactopyranoside. After further growth for 
3-4 h, the cells were harvested by continuous flow centrifugation at 
15,000 rpm at 4 “C. The cell pellet was stored at -70 “C. The following 
steps were carried out at 4 “C. Cells from the 14-liter culture were 
resuspended in 300 ml of buffer A (50 mM potassium phosphate, pH 
7.5,1 mM EDTA, 10 mM P-mercaptoethanol with 1 mM phenylmeth- 
anesulfonyl fluoride, and 2 mg/liter leupeptin (lysis buffer). Lysozyme 
(150 mg/7 ml of lysis buffer) was added to the suspension followed 
by incubation on ice for 15 min. MgCl, (1 M, 900 al) and 24 mg of 
DNase I were added, and the suspension was placed on ice for another 
15 min. The suspension was then centrifuged at 12,000 rpm for 15 
min. To the supernatant, ammonium sulfate was slowly added to a 
final concentration of 85% with gentle stirring overnight. Following 
centrifugation at 18,000 rpm for 30 min, the pellet was resuspended 
in 250 ml of lysis buffer and loaded onto a 1.5 x 3-cm MTX- 
aminohexyl-Sepharose 4B column equilibrated with buffer A. After 
extensive washing with buffer B (buffer A + 500 mM KCl) and buffer 
C (buffer B, pH 8.0) the column was eluted with FAH, (2 mg/ml in 
buffer C). The fractions containing DHFR activity were pooled and 
concentrated to 10 ml in an Amicon ultrafiltration apparatus fitted 
with a YM-10 membrane and stored at 4 “C. The enzyme was then 
passed through a 1 x 30-cm Sephadex G-50 column equilibrated with 
buffer A to remove excess substrate. Enzyme purity was evaluated by 
SDS-polyacrylamide gel electrophoresis (23). 
Protein Determination-Enzyme concentration was determined by 
both MTX titration (24) and by the Bio-Rad version of Bradford’s 
dye-binding assay (25). MTX concentration was determined spectro- 
metrically at 258 nm (EM = 23,250) and 302 nm (EM = 22,100) (26). 
Steady-state Kinetics-DHFR activity was determined by meas- 
uring the decrease in absorbance at 340 nm and at 22 “C which 
accompanied the conversion of FAH, to tetrahydrofolate and of 
NADPH to NADP’ (27, 28). Initial rates were derived from the 
change in absorbance continuously recorded with a Varian model 219 
spectrophotometer in a reaction buffer containing 50 mM Tris-HCl, 
pH 7.5. FAH, concentration was determined both spectrophotomet- 
rically at 282 nm (extinction coefficient = 2.8 X 10’ M-’ cm-‘) and 
340 nm (extinction coefficient = 6.59 x 10” M-’ cm-‘) (18). NADPH 
concentration was determined in the same way using a molar extinc- 
tion coefficient of 6.2 X lo3 M-’ cm-’ at 340 nm and 1.49 X lo4 M-' 
-’ at 259 nm (29). The K,,, values for FAH2 and NADPH were 
zzermined by varying the concentration of one substrate while 
maintaining the concentration of the second substrate at a constant 
saturating level and by measuring the initial velocity at each concen- 
tration. The data were fit to the following Michaelis-Menten equa- 
tion. 
v _ vmx WI 
Km + [Sl 
Use of a nonlinear regression program yielded values for V,,,., and 
K,,,. The k,., was calculated by dividing V,,,., by the concentration of 
enzyme used in the reaction. To maintain constant ionic strength 
over the pH range used in obtaining pH profiles of k,,,, a three- 
component buffer system was used containing 50 mM Tris, 25 IIIM 
acetate, 25 mM MES, and 100 mM NaCl (MATS buffer). 
Anti-peptide Antibodies and ELZSA-The production of antibodies 
against CNBr peptides 15-52, 53-111, and 140-186 derived from 
hDHFR has been described (14). Denatured hDHFR, obtained by 
precipitation with 10% trichloroacetic acid followed by boiling in 1% 
SDS and diluting to <0.05% SDS, was immobilized in a microtiter 
plate (0.1-0.2 kg/well). Antisera preincubated in the absence and in 
the presence of native and various ligand-complexed forms of DHFR 
(see the legend for Fig. 6) in 10 mM sodium phosphate, pH 7.5, 
containing 150 mM sodium chloride, 0.1% Tween 20, and 1% nonfat 
dry milk were assayed in these wells using glucose oxidase-conjugated 
goat-anti-rat IgG and measuring the absorbance at 405 nM in the 
presence of horseradish peroxidase, @-D-ghCOse, and 2,2’-azinobiz(3- 
ethylbenzothiazoline 6-sulfonic acid) as described (30). 
RESULTS 
Construction of the Mutant-The deletion mutant hDHFR 
des[Gly45-Lys46] was constructed by oligodeoxynucleotide-di- 
rected mutagenesis, which is based on the method of Eckstein 
and co-workers (31, 32), with mutagenesis efficiencies of 
>80%. After the mutant hDHFR cDNA was cloned into the 
pDFR vector, the entire structural gene was sequenced dem- 
onstrating that the expected deletion had been introduced 
and that no other alteration had occurred (data not shown). 
Stability of the Mutant Enzyme-The thermal stability 
experiments (Fig. 1) showed that the mutant des[Gly45-Lys46], 
in its apoenzyme form, lost more than 80% activity in less 
than 30 min at 22 “C! unlike the wild-type DHFR which 
remained fully active. The NADPH-enzyme and FAHp-en- 
zyme complexes, like their counterparts in the wild-type en- 
zyme, are quite stable (Fig. 1). The FAH2-enzyme complex 
could be stored at 4 “C! up to 3 weeks with greater than 90% 
activity remaining (data not shown). 
Kinetic Studies-The steady-state kinetic properties of the 
wild-type and mutant hDHFRs were examined in order to 
make a preliminary assessment of the effects of the mutation 
on the substrate binding properties of the enzyme. Specific 
activities were determined by MTX titration based on the 
fact that MTX is a stoichiometric tight binding inhibitor of 
DHFR (24). The titration curves for both wild-type and 
des[Gly45-Lys46] enzymes are shown in Fig. 2. There is a linear 
relationship between MTX concentration and inhibition of 
m n 
FIG. 1. Thermal stability of wild type (0) and des[Gly4’- 
Lys4’] (A) hDHFRs at 22 “C. The enzymes (0.1 nM) were incubated 
in 50 mM Tris-HCl, pH 7.5. Aliquots were removed from the incu- 
bation mixture at various time intervals as indicated and assayed. VO, 
DHFR activity at time 0; V, DHFR activity at the indicated time. A, 
enzyme alone; B, enzyme + 0.1 mM NADPH; C, enzyme + 0.1 mM 
FAHZ. 
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FIG. 2. Methotrexate titration of wild-type (0) and des 
[Gly45-Lys46] (A) DHFRs. The enzymes with the same units of 
activity were incubated with various concentrations of MTX in 50 
mM Tris-HCI, 100 FM NADPH, pH 7.5, for 2 min at 22 “C. The 
DHFR activities were monitored after addition of 50 FM FAHz for at 
least 1 min. 
TABLE I 
Steady-state properties of wild-type and mutant 
des[Gly45-Lys’Gl DHFRs 
Steady-state properties were determined by spectrophotometric 
measurements of initial velocities as a function of substrate concen- 
tration in 50 mM Tris-HCl buffer, pH 7.5. All reactions were measured 




k Specific cat activity 
PM s-1 units/mg 
Wild type 0.032 0.26 7.3 20 
des[Gly4”-Lys46] 0.036 0.29 2.9 7.8 
FIG. 3. pH dependence of k,., for the wild-type (0) and 
deletion mutant (A) DHFRs. Reaction conditions were 22 pM 
NADPH, 10 pM FAHg, 0.47 nM des[Gly’S-Lys46], and 0.34 nM wild- 
type hDHFR at 22 “C in MATS buffer. 
enzyme activity up to a 90% loss of activity for both wild type 
and mutant. The specific activity of the des[Gly45-Lys46] en- 
zyme is 7.8 units/mg (corresponding to a k,,, of 2.8 s-i), 
whereas the specific activity of wild type is 20 units/mg 
(corresponding to a k,,, value of 7.3 s-i) (19). Thus, the k,,, 
for the wild-type enzyme is about 2.5-fold greater than that 
for des[Gly45-Lys46]. 
The K, values for FAH2 and NADPH for the des[Gly45- 
LYS~~] mutant reductase were determined and the results 
compared to those of wild-type enzyme (Table I). Apparent 
K,,, values for FAH, and for NADPH for the mutant are 
approximately the same as those found for the wild-type 
enzyme (33). The pH dependence of &at for both mutant and 
wild-type hDHFR were determined, and the pH rate profiles 
are shown in Fig. 3. The des[Gly45-Lys46] hDHFR showed two 
pH optima, one at about pH 4-4.5 and another at about pH 
8-8.5, similar to that for the wild type (34, 35). 
Effects of Activating Agents-Human DHFR can be acti- 
vated to different extents by KCl, urea, and organic mercurial 
compounds such as p-hydroxymercuribenzoate (pHMB) (34). 
The effects of these activating agents were tested on the 
mutant enzyme. Fig. 4 shows the effects of KC1 and urea on 
the enzymic activities of the wild-type and mutant reductases. 
FIG. 4. The effects of urea and KC1 on the enzymic activity 
of wild-type (0) and des[Gly4’-LyP] (A) DHFRs. The enzymes 
were assayed in the presence of various concentrations of urea or KC1 
as indicated in 50 mM Tris-HCl, pH 7.5, at 22 “C. Vo, DHFR activity 
in the absence of urea or KC1; V, DHFR activity at the indicated 
concentration of urea or KCl. 
FIG. 5. The effect of pHMB on wild-type (0) and des[Gly”- 
Lys4’] (A) DHFRs. The enzymes (0.8-l pM) were incubated with a 
loo-fold molar excess of NADPH in 50 mM potassium phosphate, pH 
7.5, at 22 ‘C in the presence of a lo-fold molar excess of pHMB (0, 
A) and in the absence of pHMB (0, A). Aliquots were removed from 
the incubation mixture and assayed at the times indicated. V,, DHFR 
activity in the absence of pHMB at time 0; V, DHFR activity at the 
indicated time. 
Wild-type enzyme was activated to about 1.8-fold at 1 M KCl, 
whereas the mutant was activated significantly less (about 
1.3-fold) under the same conditions. The wild-type enzyme 
was activated about 2.8-fold at a 5 M concentration of urea 
whereas des[Gly45-Lys46] hDHFR showed a slight activation 
at low concentrations with about a 1.4-fold activation at 2 M 
urea and a rapid decline in activity at concentrations higher 
than 2 M. Fig. 5 illustrates the effects of pHMB on the enzyme 
activities of wild-type and the deletion mutant. As shown in 
Fig. 5, wild-type enzyme was activated about 4-fold when 
incubated with a lo-fold molar excess of pHMB in the pres- 
ence of NADPH, whereas des[Gly45-Lys46] was not activated 
under the same conditions. 
Binding of Antibodies to Wild Type, des[Gly45-Lys461, and 
Their Enzyme-L&and Complexes-The binding of three pep- 
tide-specific antibodies to DHFR in solution was determined 
by competitive ELISA assays in which denatured hDHFR 
was immobilized. The binding of antibodies, at an appropriate 
dilution, to immobilized antigen was assayed in the presence 
of various concentrations of native wild-type or des[Gly45- 
LYS~~] hDHFR or in the presence of the enzyme preincubated 
with a saturating concentration of folate (0.1 mM), NADPH 
(0.1 DIM), or MTX (0.2 mM) plus NADPH. As indicated in 
Fig. 6, in the case of all three antisera, native wild-type or 
deletion mutant hDHFR competed for the antibodies, inhib- 
iting their binding to the immobilized denatured enzyme in a 
concentration-dependent manner. Preincubation of the wild- 
type hDHFR with folate, NADPH, or MTX plus NADPH 
significantly inhibited antibody binding to the native enzyme 
to various degrees, shifting the curve to the right in all cases 
(Fig. 6A, I-111). Maximum inhibition of antibody binding to 
the native enzyme was produced when MTX and NADPH 
were both bound in a ternary complex. In the case of 
des[Gly45-Lys46], however, the preincubation of folate, 
NADPH, or MTX plus NADPH compared with native wild 
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PROTEIN CONCENTRATION bghl) 
FIG. 6. Competitive immunoassays using antisera to pep- 
tides 15-52 (I), 53-111 (II), and 140-186 (Ill). ELISA assays 
were carried out with denatured hDHFR as the immobilized antigen. 
Antisera to cyanogen bromide peptides 15-52, 53-111, and 140-186 
were used at l/5000, l/1000, and l/4000 dilutions, respectively, due 
to differences in antibody titers. The antisera (50 ~1) were preincu- 
bated for 2 h at 22 “C in the absence or in the presence of various 
concentrations of: A, wild-type hDHFR or its complexes with ligands; 
B, deletion mutant DHFR or its complexes with ligand(s). 0, native 
enzyme alone; A, enzyme + folate; 0, enzyme + NADPH; X, enzyme 
+ MTX + NADPH. The antibody solutions were then applied directly 
onto the microtiter plates and assayed as described under “Experi- 
mental Procedures.” A,,, absorbance in the absence of either wild- 
type or mutant DHFRs during the preincubation; A, absorbance in 
the presence of various forms of wild-type or mutant DHFRs at the 
indicated concentration. 
type had much less effect on the antibody binding to the 
native enzyme (Fig. 6B, I-111), especially in the binary com- 
plexes. The data in Fig. 6 are described in Table II in terms 
of the concentration of native wild-type or mutant hDHFR 
needed to inhibit antibody binding to denatured hDHFR by 
approximately 50% either in the absence or in the presence 
of various ligands. The values for wild type-ligand complexes 
range from 2-fold to over 16-fold greater than the values for 
the deletion mutant. 
DISCUSSION 
Studies of ligand-induced conformational changes in DHFR 
deduced from kinetic studies (36, 37) and NMR or fluores- 
cence experiments (5-9, 38) have focused on bacterial en- 
zymes. Changes have been localized in the environment of 
amino acid residues located outside the active site upon the 
binding of NADP+, NADPH, and anti-folates such as tri- 
methoprim and MTX. In order to understand the conforma- 
tional changes of hDHFR and the role of “loop” regions in 
such changes as well as in enzyme function, we have con- 
structed, by site-directed mutagenesis, a hDHFR mutant, 
des[Gly45-Lys46], with a 2-residue deletion in a loop region 
consisting of residues 40-46. The x-ray structure of hDHFR 
showed that these 2 residues are distant from the active site 
of the enzyme (16). The thermal parameter main chain B 
value for this highly exposed loop region is 0.376 nm’, com- 
pared with 0.119 nm* for the rigid core of the protein, indi- 
cating that this region has a high thermal mobility. The 
conformational changes of DHFR caused by either ligand 
binding or activating agents were most probably occurring in 
mobile regions of protein. Since certain antigenic sites must 
be mobile for recognition by antibody, these sites might be 
involved in such conformational changes. Experiments using 
anti-peptide antibodies showed that the wild-type hDHFR, in 
the presence of NADPH, folate, or MTX and NADPH, bound 
significantly less of the antibodies than the apoenzyme (cf. 
Fig. 6). The antigenic sites became either inaccessible or lost 
sufficient flexibility for antibody binding due to the confor- 
mational changes in DHFR (14). From results of peptide 
mapping, Gly45 and Ly@ are part of an antigenic epitope (15). 
This information suggests that the loop region 40-46 is in- 
volved in the overall conformational constraints of the en- 
zyme molecule. 
From steady-state kinetic studies (Table I), the K,,, values 
of the deletion mutant DHFR for both FAHz and NADPH 
are similar to those of the wild-type enzyme. The results 
suggest that deletion of 2 residues in the loop region 40-46 
has little or no effect on substrate binding. This was not 
totally unexpected since this loop is far from the substrate 
binding site cleft. In contrast, the V,,, value of des[Gly45- 
Lys4’j] is 2.8-fold lower than that of the wild type. This 
observation may indicate that the loss of 2 residues from the 
loop region 40-46 has decreased the flexibility of this region 
which, in turn, results in a decrease in enzyme catalytic 
efficiency. The des[Gly45-Lys46] mutant, in its apoenzyme 
form, is very unstable (Fig. 1) and in the absence of substrate, 
activity is rapidly lost. Due to this property, we were unable 
to determine the Kd values of mutant enzyme for substrate 
and cofactor. Crystal structure studies of chicken liver DHFR, 
which has a structure similar to hDHFR, indicate that there 
is a nonbonded contact between loop 40-46 and another loop 
region at residues loo-108 (17). This contact might be dis- 
rupted due to the deletion of Gl~~~-Lys~~ in the loop 40-46. 
This nonbonded contact could be an important factor for 
maintaining the enzyme tertiary structure. 
As with most DHFRs from vertebrate sources, hDHFR can 
be activated over a limited concentration range by salt, urea, 
and organomercurial compounds such as pHMB (4, 34). In- 
vestigations on the mechanism of activation have suggested 
that a general unfolding of the native protein is a common 
feature (19, 39, 40). Compared with wild type enzyme, acti- 
vation of des[Gly45-Lys46] hDHFR by KC1 or urea is much 
less at each corresponding concentration (Fig. 4, A and B). 
Unlike wild type, the mutant DHFR was not activated by 
pHMB (Fig. 5). The reduction in the ability to be activated 
by these agents in the case of the mutant enzyme might be 
due to the 2-residue deletion in loop 40-46 impairing the 
TABLE II 
Concentration of wild-type and des[Gly45-Lys461 DHFRs and their complexes with ligands required for 50% 
inhibition of anti-peptide antibody binding to denatured hDHFR 




NOI+ Folate NADPH MTX + NADPH 
WT DM WTIDM WT DM WTIDM WT DM WTIDM WT DM WTIDM 
15-52 4.2 3.3 1.27 18.0 4.0 4.5 36 5.5 6.54 38 18 2.11 
53-111 3.8 2.6 1.46 >50 3 >16 k-50 3 >16 >40 4.5 >ll 
140-186 5.8 3.5 1.65 40 4.5 8.89 40 4.5 8.89 40 16 2.5 
a WT, wild type; DM, deletion mutant. 
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limited unfolding of the enzyme molecule. In other words, the 
loop might be involved in the unfolding process of wild-type 
enzyme which occurs concomitantly with activation. Addi- 
tionally, deletion mutant activity decreased rapidly at higher 
salt and urea concentrations at which the wild-type enzyme 
still can be activated. The mutant is also much more suscep- 
tible to denaturation which is consistent with the instability 
of this enzyme. 
To probe the conformational states of the mutant and wild- 
type enzymes and their ligand complexes we have employed 
competitive ELBA using sequence-specific anti-human 
DHFR peptide antibodies. The cyanogen bromide peptides 
from hDHFR were homogeneous and corresponded to the 
sequences 15-52, 53-111, and the COOH-terminal sequence 
140-186 (14). Antisera against these peptides were highly 
specific for the corresponding peptides. The experiments in- 
dicate that, upon binding to the various ligands, wild-type 
enzyme exhibits a significant reduction in the ability to bind 
to the three peptide antibodies. The inhibition occurred to 
various extents with the different ligands used and, in most 
cases, ternary complexes bound less antibody than binary 
complexes (Fig. 6 and Table II). Ratnam et al. (14) have 
demonstrated that the ligands alone have no detectable effect 
on antibody binding to denatured DHFR immobilized in the 
microtiter plates and no direct interference with antibody 
binding in solution. The loss of antigenicity indicates either 
that the region where the antibody binds has become sterically 
inaccessible to the peptide antibody or that it has adopted a 
significantly different or more constrained conformation (41). 
The dramatic reduction in antibody binding suggests that 
conformational changes induced by ligands have indeed oc- 
curred and that these changes involve different portions of 
the protein molecule, since the binding of all three anti- 
peptide antibodies was decreased following ligand binding. In 
contrast, the binding of ligand(s) with the deletion mutant 
enzyme had much less effect on the inhibition of antibody 
binding, especially in binary complexes (Fig. 6). Ligand-bound 
des[Gly45-Lys46] achieved about a 90% inhibition at a 50 pg/ 
ml concentration as did the apoenzyme, but ligand-bound 
wild type only achieved about 70% inhibition at the same 
protein concentration. To achieve 50% inhibition required at 
least a 2-fold greater amount of protein of ligand-bound wild 
type as it did for the corresponding ligand-bound mutant 
enzyme. These results clearly indicate that the conforma- 
tional changes of wild type induced by ligand are more pro- 
nounced than that of the mutant. The results also show that 
the 2-residue deletion in the 40-46-100~ region has affected 
the antibody binding not only in the peptide 15-52 region but 
also in the peptide 53-111 and 140-186 regions. Thus, it 
appears that the loop region 40-46 is important for both 
modulating conformational changes in the protein and for 
communicating the effects of ligand binding. 
In general, our studies on the deletion mutant des[Gly45- 
Ly@] suggest that the flexible loop between residues 40 and 
46 plays an important role in ligand-induced conformational 
changes in the DHFR molecule and, perhaps, in the partial 
unfolding of the protein during activation. The loss of flexi- 
bility in this loop region results in specific constraints on the 
conformational changes which can occur in the enzyme mol- 
ecule upon ligand binding. The deletions also result in a 
decrease in the catalytic efficiency of the enzyme. Little effect 
on the apparent values of K,,, for both FAH, and NADPH 
were observed implying that the loop region 40-46 may be 
more involved in catalytic efficiency than in substrate or 
coenzyme binding to hDHFR. 
Acknowledgments-We wish to thank Philip Smith, Tavner Del- 
camp, and Michael DeYarman for their technical help. We also thank 
Valerie Murphy for preparing the manuscript. During the course of 
this work use was made of the Harold and Helen McMaster Recom- 
binant DNA Laboratory. 
1. Freisheim, J. H., and Matthews, D. A. (1984) in Folute Antagonists 
as TheraDeutic Agents (Sirotnak. F. M., Burchall, J. J., 
Ensminger, W. D.,and Montgomery, J. A., eds) Vol. l,.pp. 69: 
131, Academic Press, Orlando, FL 
2. Hitchings, G. H., and Baccanari, D. P. (1984) in Folute Antugo- 
3. 
nists as Therapeutic Agents (Sirotnak, F. M., Burchall, J.-J., 
Ensminger, W. D., and Montgomery, J. A., eds) Vol. 1, pp. 151- 
172, Academic Press, Orlando, FL 
Montgomery, J. A., and Piper, J. R. (1984) in Folate Antagonists 
us Therapeutic Agents (Sirotnak, F. J., Burchall, J. J., Ensmin- 
ger, W. D., and Montgomery, J: A., eds) Vol. 1, pp. 219-260, 
Academic Press, Orlando, FL 
4. Blakley, R. L. (1984) in Folutes and Pterins (Blakley, R. L., and 





Bevan, A. W., Birdsall, B., Roberts, G. C. K., Feeney, J., Gronen- 
born, A., Clore, G. M., and Burgen, A. S. V. (1983) Chemistry 
and Biology of Pteridines: Proceedings of the Seventh Internu- 
tionul Symposium on Pteridines and Folic Acid Derivatives. 
Chemical, Biological and Clinical Aspects. (Blair, J. A., ed) pp. 
557-561, Walter de Gruyter, Berlin 
Birdsall, B., Burgen, A. S. V., and Roberts, G. C. K. (1980) 
Biochemistry 19, 3732-3737 
Birdsall, B., Bevan, A. W., Pascual, C., Roberts, G. C. K., Feeney, 
J., Gronenborn, A., and Clore, G. M. (1984) Biochemistry 23, 
4733-4742 
8. Gronenborn, A., Birdsall, B., Hyde, E. I., Roberts, G. C. K., 





Feeney, J., Roberts, G. C. K., Thomson, J. W., King, R. W., 
Griffiths. D. V.. and Bureen. A. S. V. (1980) Biochemistry 19. 
2316-2321 - 
” 
Matthews, D. A., Alden, R. A., Freer, S. T., Xuong, N., and Kraut, 
J. (1979) J. Biol. Chem. 254.4144-4151 
Matthews, D. A., Bolin, J. T., Burridge, J. M., Felman, D. J., 
Volz, K. W., Kaufman, B. T., Beddel, C. R., Champness, J. N., 








Matthews, D. A., Bolin, J. T., Burridge, J. M., Filman, D. J., 
Volz, K. W., and Kraut, J. (1985) J. Viol. Chem. 260, 392-399 
Ratnam, M., Delcamp, T. J., and Freisheim, J. H. (1986) Bio- 
chemistry 25,5453-5459 
Ratnam, M., Tan, X., Prendergast, N. J., Smith, P. L., and 
Freisheim. J. H. (1988) Biochemistry 27.4800-4804 
Tan, X., Ratnam, M., Huang, S., Smith, P: L., and Freisheim, J. 
H. (1990) J. Biol. Chem. 265, 8022-8026 
Oefner, C., D’Arcy, A., and Winkler, F. K. (1988) Eur. J. Biochem. 
174,377-385 
Volz, K. W., Matthews, D. A., Alden, R. A., Freer, S. T., Hansch, 












Blakley, R. L. (1960) Nature 188, 231-232 
Prendergast, N. J., Delcamp, T. J., Smith, P. L., and Freisheim, 
J. H. (1988) Biochemistry 27, 3664-3671 
Sanger, F., Nicklen, S., and Coulson, A. (1977) Proc. Natl. Acud. 
Sci. U. S. A. 74,5463-5467 
Biggin, M. D., Gibson, T. J., and Hong, G. J. (1983) Proc. Nutl. 
Acud. Sci. U. S. A. 80, 3963-3965 
Agellon, L., and Chen, T. (1986) Gene Anal. Tech. 3,86-89 
Laemmli, U. K. (1970) Nature 227,680-685 
Williams, J. W., Morrison, J. F., and Duggleby, R. G. (1979) 
Biochemistry 18, 2567-2573 
Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 
Seeger, D. R., Cosulich, D. B., Smith, J. M., and Hultquist, M. E. 
(1949) J. Am. Chem. Sot. 71, 1753-1758 
Kempton, R. J., Black, A. M., Amstead, G. M., Kumar, A. A., 
Blankenshin. D. T.. and Freisheim. J. H. (1982) J. Med. Chem. 
24,475-477 
28. Appleman, J. R., Beard, W. A., Delcamp, T. J., Prendergast, N. 
J., Freisheim. J. H.. and Blaklev. R. L. (1989) J. Biol. Chem. 
264, 2625-2633 
REFERENCES 










Mutagenesis of Dihydrofolate Reductase 
29. Horecker, B. L., and Kornberg, A. (1948) J. Biol. Chem. 1'75, 36. Penner, M. H., and Freiden, C. (1985) J. Biol. Chem. 260,5366- 
385-390 5369 
30. Hochschwender, S., Langeborg, L. K., Schneider, D. W., and 
Lindstrom, J. M. (1985) in Hybridomas in Biotechnology and 
37. Dunn, S. M. J., and King, R. W. (1980) Biochemistry 19, 766- 
Medicine (Springer, T., ed) pp. 223-238, Plenum Publishing 773 
Corp., New York 38. Kimber, B. J., Griffiths, D. V., Birdsall, B., King, R. W., Scudder, 
31. Nakamaye, K., and Eckstein, F. (1986) Nucleic Acids Res. 14, P., Feeney, J., Roberts, G. C. K., and Burgen, A. S. V. (1977) 
9679-9698 Biochemistry16,3492-3500 
32. Sayers, J. R., Schmidt, W., and Eckstein, F. (1988) Nucleic Acids 39. Huennekens, F. M., Mell, G. P., Harding, N. G. L., Gundersen, 
Res. 16, 791-802 
33. Huang, S., Delcamp, T. J., Tan, X., Smith, P. L., Prendergast, 
L. E., and Freisheim, J. H. (1970) in Chemistry and Biology of 
N. J., and Freisheim, J. H. (1989) Biochemistry 28,471-478 
Pteridines (Iwai, K., Akino, M., Groto, M., and Iwanami, Y., 
34. Delcamp, T. J., Susten, S. S., Blankenship, P. T., and Freisheim, 
eds) pp. 329-350, International Academic Printing, Tokyo 
J. H. (1983) Biochemistry 22, 633-639 40. Barbehenn, E. K., and Kaufman, B. T. (1982) Arch. Biochem. 
35. Schweitzer, B. I., Sirmatkandada, S., Gritsman, H., Sheridan, R., Biophys. 219,236-247 
Vankataraghavan, R., and Bertino, J. R. (1990) J. Biol. Chem. 41. Gariepy, J., Mietzner, T. A., and Schoolnik, G. K. (1986) Proc. 
264,20786-20795 Natl. Acad. Sci. U. S. A. 83,8888-8892 
 by guest, on M
arch 31, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
